Budesonide Nasal
ApprovedActive 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Epigenetic Effects of Intranasal Steroids
Conditions
Epigenetic Effects of Intranasal Steroids, Environmental Exposure
Trial Timeline
Jan 7, 2021 → Dec 31, 2027
NCT ID
NCT04342039About Budesonide Nasal
Budesonide Nasal is a approved stage product being developed by Johnson & Johnson for Epigenetic Effects of Intranasal Steroids. The current trial status is active. This product is registered under clinical trial identifier NCT04342039. Target conditions include Epigenetic Effects of Intranasal Steroids, Environmental Exposure.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04342039 | Approved | Active |